AutoLumo CLIA Inflammatory Markers, 100 Tests

The AutoLumo CLIA Inflammatory Marker Microparticles Series provides a comprehensive panel of chemiluminescent immunoassay (CLIA) reagents designed for the quantitative detection of inflammatory and fibrosis-related biomarkers in human serum or plasma.

Based on magnetic microparticle CLIA technology, these reagents ensure high sensitivity, accuracy, and reproducibility, supporting the early detection, differential diagnosis, and monitoring of systemic inflammation, sepsis, cardiovascular events, and liver fibrosis.

All reagents are compatible with AutoLumo CLIA Analyzer Systems, offering automated, high-throughput performance for clinical laboratories, hospitals, and research centers.

Key Features

• High Analytical Sensitivity: Enables detection of trace inflammatory and fibrotic markers.
• Magnetic Microparticle Technology: Provides stable and reproducible chemiluminescent signals.
• Broad Clinical Utility: Supports diagnosis of infection, inflammation, and hepatic fibrosis.
• Automation Ready: Fully compatible with AutoLumo CLIA Analyzers.
• Rapid Turnaround: Ideal for emergency, critical care, and chronic disease monitoring.
• CE-Marked Kits: Validated for clinical diagnostic applications.
• Stable Formulation: Ensures consistent assay performance and reliability.

Product Range

A. Inflammatory Markers

Applications:

• Infection and Sepsis: PCT, CRP, and IL-6 for early diagnosis and severity assessment.
• Inflammatory Disorders: Quantification of systemic inflammation and immune response.
• Thrombotic and Cardiovascular Risk: D-Dimer for coagulation abnormalities and embolism detection.
• Post-Surgical and Critical Care Monitoring: Evaluation of inflammatory status and prognosis.

B. Hepatic Fibrosis Markers

Applications:

• Liver Fibrosis and Cirrhosis Evaluation: Combined detection of PIIINP, Col IV, LN, and HA.
• Chronic Hepatitis Management: Non-invasive alternative to biopsy for fibrosis monitoring.
• Drug-Induced Liver Injury (DILI): Assessment of liver extracellular matrix changes.
• Fibrosis Progression and Regression Monitoring: Supports clinical decision-making in hepatology.

Clinical Applications

• Systemic Inflammation Detection: hs-CRP and IL-6 for inflammatory and autoimmune conditions.
• Sepsis and Infection Diagnosis: PCT and CRP for early differentiation between bacterial and viral infections.
• Thromboembolic Disease Monitoring: D-Dimer for evaluating coagulation and clotting disorders.
• Liver Fibrosis Assessment: Fibrotic markers for monitoring chronic liver diseases (HBV, HCV, NAFLD).
• Comprehensive Inflammation and Fibrosis Profiling: Suitable for multi-marker diagnostic panels.

Performance Characteristics

• Detection Method: Chemiluminescent Immunoassay (CLIA)
• Technology: Magnetic Microparticle-Based Sandwich Immunoassay
• Sample Type: Human Serum or Plasma
• Precision: Coefficient of Variation (CV) ≤ 10%
• Storage Conditions: 2–8°C, protected from light
• Shelf Life: 12 months from manufacturing date

Unique Advantages

• Comprehensive inflammation and fibrosis panel for diagnostic and monitoring use.
• CE-marked assays for clinical compliance and reliability.
• Automated testing for high-throughput clinical workflows.
• High sensitivity and reproducibility for early detection and disease staging.
• Multiparameter capability supporting comprehensive inflammatory profiling.

The AutoLumo CLIA Inflammatory Marker Microparticles Series delivers a robust suite of chemiluminescent reagents for precise detection of inflammatory and fibrotic biomarkers.

Powered by magnetic microparticle CLIA technology, the series ensures rapid, accurate, and reproducible results for critical diagnostic applications, from sepsis and infection management to liver fibrosis monitoring.

An essential tool for clinical laboratories, hospitals, and hepatology centers, these assays combine high sensitivity, automation compatibility, and CE-certified quality, making them a cornerstone of inflammatory and fibrosis diagnostics.